ITCI INTRA-CELLULAR THERAPIES INC revenue, earnings and financials
For the quarter ended December 31, 2024, INTRA-CELLULAR THERAPIES INC reported revenue of $199M (up 50.8% from a year earlier), net income of −$16.9M and diluted EPS of −$0.16; over the last four quarters revenue was $681M and net income −$74.7M; for the fiscal year ended December 2024 revenue was $681M, up 46.6% on the year before.
ITCI annual revenue and earnings
- Fiscal year ended Dec 2024: revenue $681M, gross profit n/a, operating income −$117M, net income −$74.7M (margin -11.0%), EPS −$0.72
- Fiscal year ended Dec 2023: revenue $464M, gross profit n/a, operating income −$159M, net income −$140M (margin -30.1%), EPS −$1.46
- Fiscal year ended Dec 2022: revenue $250M, gross profit n/a, operating income −$264M, net income −$256M (margin -102.4%), EPS −$2.72
- Fiscal year ended Dec 2021: revenue $83.8M, gross profit n/a, operating income −$286M, net income −$284M (margin -339.0%), EPS −$3.50
ITCI quarterly revenue and earnings
- Quarter ended Dec 31, 2024: revenue $199M (up 50.8% year over year), net income −$16.9M, EPS −$0.16
- Quarter ended Sep 30, 2024: revenue $175M (up 39.0% year over year), net income −$26.3M, EPS −$0.25
- Quarter ended Jun 30, 2024: revenue $161M (up 45.7% year over year), net income −$16.2M, EPS −$0.16
- Quarter ended Mar 31, 2024: revenue $145M (up 52.0% year over year), net income −$15.2M, EPS −$0.16
- Quarter ended Dec 31, 2023: revenue $132M (up 50.3% year over year), net income −$28.6M, EPS −$0.30
- Quarter ended Sep 30, 2023: revenue $126M (up 75.6% year over year), net income −$24.3M, EPS −$0.25
- Quarter ended Jun 30, 2023: revenue $111M (up 99.3% year over year), net income −$42.8M, EPS −$0.45
- Quarter ended Mar 31, 2023: revenue $95.3M (up 172.3% year over year), net income −$44.1M, EPS −$0.46
- Quarter ended Dec 31, 2022: revenue $87.9M (up 242.3% year over year), net income −$44.0M, EPS −$0.45
- Quarter ended Sep 30, 2022: revenue $71.9M (up 223.6% year over year), net income −$53.5M, EPS −$0.57
- Quarter ended Jun 30, 2022: revenue $55.6M (up 177.2% year over year), net income −$86.6M, EPS −$0.92
- Quarter ended Mar 31, 2022: revenue $35.0M (up 120.4% year over year), net income −$72.1M, EPS −$0.78
- Quarter ended Dec 31, 2021: revenue $25.7M, net income −$85.7M, EPS −$1.05
- Quarter ended Sep 30, 2021: revenue $22.2M, net income −$76.9M, EPS −$0.95
- Quarter ended Jun 30, 2021: revenue $20.0M, net income −$68.7M, EPS −$0.85
- Quarter ended Mar 31, 2021: revenue $15.9M, net income −$52.7M, EPS −$0.65
ITCI cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$73.2M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$124M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$270M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$260M, share buybacks n/a
ITCI balance sheet
- Dec 31, 2024: cash $307M, total assets $1.37B, total liabilities $218M, shareholders' equity $1.15B
- Sep 30, 2024: cash $464M, total assets $1.32B, total liabilities $180M, shareholders' equity $1.14B
- Jun 30, 2024: cash $693M, total assets $1.32B, total liabilities $176M, shareholders' equity $1.14B
- Mar 31, 2024: cash $140M, total assets $747M, total liabilities $148M, shareholders' equity $599M
- Dec 31, 2023: cash $148M, total assets $728M, total liabilities $137M, shareholders' equity $591M
- Sep 30, 2023: cash $99.4M, total assets $718M, total liabilities $117M, shareholders' equity $601M
- Jun 30, 2023: cash $142M, total assets $714M, total liabilities $107M, shareholders' equity $607M
- Mar 31, 2023: cash $75.7M, total assets $722M, total liabilities $94.5M, shareholders' equity $628M
What is ITCI's revenue?
INTRA-CELLULAR THERAPIES INC reported $681M of revenue over its last four quarters, through December 31, 2024.
Is ITCI profitable?
No. INTRA-CELLULAR THERAPIES INC lost $74.7M over the last four quarters.
What is ITCI's EPS?
Diluted earnings per share over the last four quarters were −$0.73; −$0.16 in the latest quarter.